Form 4: Acrivon Therapeutics Executives Acquire Stock Options

Acrivon Therapeutics' CEO and EVP of Business Operations were granted stock options, with vesting schedules tied to continued service.

Summary

• Acrivon Therapeutics' President and CEO, Peter Blume-Jensen, was granted stock options for 225,226 shares at an exercise price of $5.70 on March 1, 2024.
• These options vest 25% on March 1, 2025, and the remaining 75% vest in 36 equal monthly installments thereafter, contingent on continued service.
• Peter Blume-Jensen also indirectly holds options for 90,090 shares through his spouse, Kristina Masson, who is the EVP of Business Operations.
• Kristina Masson was also granted stock options for 90,090 shares at an exercise price of $5.70 on March 1, 2024.
• These options also vest 25% on March 1, 2025, and the remaining 75% vest in 36 equal monthly installments thereafter, contingent on continued service.
• Both Peter Blume-Jensen and Kristina Masson disclaim beneficial ownership of the options held by their spouse, except to the extent of their pecuniary interest.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of granting stock options to executives, which is generally viewed positively as it aligns interests. There are no negative implications.

Positives

• The granting of stock options aligns the interests of the executives with the long-term success of the company.
• The vesting schedule encourages continued service and commitment from the executives.
• The options provide a potential incentive for the executives to increase shareholder value.

Risks

• The value of the stock options is dependent on the future performance of the company's stock price.
• If the executives leave the company before the options fully vest, they may forfeit some or all of the options.

Future Outlook

The document does not contain any forward-looking statements or guidance.

Industry Context

The granting of stock options to executives is a common practice in the biotechnology industry to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in the biotech industry, often with vesting schedules tied to continued employment.
• The vesting schedule of 25% after one year and the remainder over 36 months is a typical vesting schedule for stock options.
• The exercise price of $5.70 is likely based on the current market price of the stock at the time of the grant.

Stakeholder Impact

• Shareholders may view the stock option grants positively as they incentivize management to increase shareholder value.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, executive compensation, insider trading, vesting, Acrivon Therapeutics, ACRV, Peter Blume-Jensen, Kristina Masson